LABF

Laboratorios Farmaceuticos Rovi S.A

LABFF.US rovi.es + Research + Basket
Employees 2,470
Phone 34 91 021 30 00
Fiscal year end December
Address Calle José Isbert, 2, Pozuelo de Alarcón, Spain, 28223
67.17
+0.00 (+0.00%)
USD · PINK
52-week range
67.17
90.61
Trading at 0% of the 52-week range
Market Cap
3.44B
P/E Ratio
15.92
Forward P/E
36.76
Book Value
15.39
Div. Yield
1.43%
% Institutions
16.41%
% Insiders
68.20%

1 Year

-25.0%

3 Year

+35.5%

10 Year

+48.2%
Description

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.

Actions

Add an action for LABFF.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Juan Lopez-Belmonte Encina Chairman & CEO NA
Mr. Ivan Jorge Lopez-Belmonte Encina Second Deputy Chairman and Chief Commercial & Development Officer NA
Mr. Javier Lopez-Belmonte Encina First Deputy Chairman, GM of Industrial Operations & CFO NA
Ms. María Álvarez Solas Chief Operating Officer NA
Ms. Marta Campos Martínez Head of Investor Relations NA
Ms. Mercedes Benítez del Castillo Sánchez Chief Legal Officer NA
Ms. Alicia Hurtado Morales Chief Compliance Officer NA
Ms. Rosario Perucha Pérez Marketing Director NA
Mr. Francisco Javier Angulo García Human Resources Manager NA
Mr. Miguel Ángel Ortega Sánchez Chief Industrial Officer NA

Financial Highlights

▼
Market Cap: $3.44B
EBITDA: $175.96M
P/E Ratio: $15.92
Book Value: $15.39
Dividend/Share: $0.96
Dividend Yield: 1.43%
Earnings/Share: $4.22
Profit Margin: 23.96%
Operating Margin: 9.42%
ROA (TTM): 9.44%
ROE (TTM): 28.65%
Revenue (TTM): $773.05M
Revenue/Share (TTM): $15.12
Earnings Growth (YOY): 246.70%
Revenue Growth (YOY): 20.00%

Valuation Metrics

Enterprise Value: $3.50B
Trailing P/E: 15.92
Forward P/E: 36.76

Shares Statistics

Shares Outstanding: 51.14M
Shares Float: 16.20M
% Insiders: 68.20%
% Institutions: 16.41%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$743.20M
Cost of Goods Sold
adjust
$-291.72M
Gross Profit
subtotal
$451.48M
SG&A
adjust
$-35.97M
R&D
adjust
$-37.78M
Other Operating Expense
adjust
$-204.66M
Operating Income
subtotal
$173.08M
Other / Non-Operating Items
adjust
$-32.69M
Net Income
subtotal
$140.39M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about LABFF.US!